Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

882P - Initial analyses of anti-PD-1 antibody plus chemoradiotherapy in patients with recurrent or metastatic head and neck cancer

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Head and Neck Cancers

Presenters

Lu Li

Citation

Annals of Oncology (2021) 32 (suppl_5): S786-S817. 10.1016/annonc/annonc704

Authors

L. Li1, M. Feng1, L. Chen2, L. Yan2, Y. Huang1

Author affiliations

  • 1 Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 610000 - Chengdu/CN
  • 2 Radiotherapy, Chengdu Medical College, 610000 - Chengdu/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 882P

Background

Immune checkpoint inhibitors (ICI) in recurrent or metastatic head and neck cancer has shown clinical activity, but the objective response rate for single-agent ICI therapy is poor. We aimed to test whether anti-PD-1 antibody may act synergistically with chemoradiotherapy to improve responses.

Methods

We conducted a retrospective study of anti-PD-1 antibody combined with chemoradiotherapy in pts with recurrent or metastatic head and neck cancer from August 2018 to April 2021. 15 pts received a 60–68Gy total dose (2.0–2.2Gy per session) for recurrent lesions, 37 pts received SBRT for 1-4 metastases lesions with the median dose of 64Gy (BED 39-100Gy), anti-PD-1 antibody (pembrolizumab or toripalimab or camrelizumab or sintilimab) and platinum were given during radiotherapy. ORR was the primary outcome and DOR and PFS were secondary outcomes.

Results

Of 52 efficacy-evaluable pts, 38 were men, median age was 50 (24-75) years. Primary site was nasopharynx (N=32) and non-nasopharynx (N=20). 37 had metastatic and 15 recurrent disease. After a median follow-up of 11.2 months (range 1-27months), ORR and DCR were 76.9% (95% CI 65.4-88.4%) and 92.3% (95% CI 85.1-99.5%). ORR of nasopharynx and non-nasopharyngeal pts was 87.5% and 60% respectively (P=0.022). ORR of local recurrence and distant metastases pts was 78.4% and 73.3% respectively (P=0.696). Median DOR was 15months (95% CI: 10.0-20.1months), median PFS was 15.0 months (95% CI: 9.0–20.9months), 6-month and 1-year PFS rate were 76.4% and 57.7%. Median overall survial was not reached. Nasopharynx had significantly longer survival compared to non-nasopharyngeal pts (mPFS: 18 vs.7months, P=0.000), and local recurrence pts had a trend towards better survival than distant metastases (mPFS 18 vs. 15months, P=0.952). The most common treatment-related adverse events above grade 3 were leucopenia (31.3%), neutropenia (18.8%) and thrombocytopenia (12.5%). 22 pts received chest radiotherapy and 27.3% of pts had all grades of radiation-induced pneumonia events.

Conclusions

Anti-PD-1 antibody in combination with chemoradiotherapy shows a promising activity in patients with recurrent or metastatic head and neck cancer and an acceptable toxicity.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Sichuan Science and technology program (fund No. 2021JDRC0146); Immunoradiotherapy research fund project of radiotherapy and Oncology Society of Chinese Medical Association (fund No. Z-2017-24-2020).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.